The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.
Every patient treated by rituximab off -label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (France) is eligible for the study, whatever the dose and the number of planned infusions. The enrollment is definitive at the time the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Pharmacovigilance. Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco- immunological studies.
Study Type
OBSERVATIONAL
Enrollment
35
patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
Service de médecine interne, hôpital Purpan, place du Dr Baylac
Toulouse, France
Occurrence of a serious adverse events
Time frame: Day 14, Week 6, Month 6, Month 12 and Month 18
Type, severity and frequency of all other adverse events occurring in the year following rituximab
Time frame: Day 14, Week 6, Month 6, Month 12 and Month 18
Factors that may influence the occurrence of infectious adverse events
Time frame: Day 14, Week 6, Month 6, Month 12 and Month 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.